BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of prostaglandin E1 and its main metabolites after intracavernous injection and short-term infusion of prostaglandin E1 in patients with erectile dysfunction. 1997

W Cawello, and H Schweer, and B Dietrich, and H W Seyberth, and D Albrecht, and A Fox, and H Hohmuth
Schwarz Pharma AG, Monheim am Rhein, Childrens Hospital, University of Marburg, Germany.

OBJECTIVE Alprostadil (prostaglandin E1) is the preferred monotherapy for intracavernous injection in the diagnosis and treatment of erectile dysfunction. Our study was designed to evaluate whether there is a difference in the pharmacokinetics of prostaglandin E1 and its main metabolites after intracavernous injection or short-term intravenous infusion. In addition, we also investigated the influence of the erectile response on prostaglandin E1 kinetics after intracavernous injection. METHODS A total of 24 patients with erectile dysfunction received, in a randomized order at an interval of 5 hours, an intracavernous injection or a 30-minute intravenous infusion of 20 microg. of alprostadil alfadex (prostaglandin E1). Venous blood samples were obtained 5 minutes before and at various times after the applications. We used highly sensitive gas chromatography/double-mass spectrometry method to measure prostaglandin E1 and its metabolites in plasma. RESULTS We demonstrated the presence of relevant systemic blood levels of prostaglandin E1 and its metabolites immediately after intracavernous injection. We found significantly lower systemic prostaglandin E1 concentrations between 7 and 20 minutes after intracavernous injection in patients with an erectile response compared with those without. CONCLUSIONS We found significant systemic concentrations of prostaglandin E1 and its metabolites after intracavernous injection. The systemic presence did not lead to significant changes in vital signs.

UI MeSH Term Description Entries
D007172 Erectile Dysfunction The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction. Impotence,Male Impotence,Male Sexual Impotence,Dysfunction, Erectile,Impotence, Male,Impotence, Male Sexual,Sexual Impotence, Male
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007267 Injections Introduction of substances into the body using a needle and syringe. Injectables,Injectable,Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000527 Alprostadil A potent vasodilator agent that increases peripheral blood flow. PGE1,Prostaglandin E1,Caverject,Edex,Lipo-PGE1,Minprog,Muse,PGE1alpha,Prostaglandin E1alpha,Prostavasin,Prostin VR,Prostine VR,Sugiran,Vasaprostan,Viridal,Lipo PGE1
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator
D018592 Cross-Over Studies Studies comparing two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. In the case of two treatments, A and B, half the subjects are randomly allocated to receive these in the order A, B and half to receive them in the order B, A. A criticism of this design is that effects of the first treatment may carry over into the period when the second is given. (Last, A Dictionary of Epidemiology, 2d ed) Cross-Over Design,Cross-Over Trials,Crossover Design,Crossover Studies,Crossover Trials,Cross Over Design,Cross Over Studies,Cross Over Trials,Cross-Over Designs,Cross-Over Study,Crossover Designs,Crossover Study,Design, Cross-Over,Design, Crossover,Designs, Cross-Over,Designs, Crossover,Studies, Cross-Over,Studies, Crossover,Study, Cross-Over,Study, Crossover,Trial, Cross-Over,Trial, Crossover,Trials, Cross-Over,Trials, Crossover

Related Publications

W Cawello, and H Schweer, and B Dietrich, and H W Seyberth, and D Albrecht, and A Fox, and H Hohmuth
Intracavernous prostaglandin E1 in erectile dysfunction.
January 1994, The Clinical investigator,
W Cawello, and H Schweer, and B Dietrich, and H W Seyberth, and D Albrecht, and A Fox, and H Hohmuth
Long-term intracavernous self-injection with prostaglandin E1 for the treatment of erectile dysfunction.
February 1996, International journal of andrology,
W Cawello, and H Schweer, and B Dietrich, and H W Seyberth, and D Albrecht, and A Fox, and H Hohmuth
Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction.
October 1994, Paraplegia,
W Cawello, and H Schweer, and B Dietrich, and H W Seyberth, and D Albrecht, and A Fox, and H Hohmuth
Intracavernous self-injection of prostaglandin E1 in the therapy of erectile dysfunction.
January 1989, VASA. Supplementum,
W Cawello, and H Schweer, and B Dietrich, and H W Seyberth, and D Albrecht, and A Fox, and H Hohmuth
Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction.
February 1999, International journal of impotence research,
W Cawello, and H Schweer, and B Dietrich, and H W Seyberth, and D Albrecht, and A Fox, and H Hohmuth
[Intracavernous injection of prostaglandin E1 as a diagnostic test in erectile dysfunction].
January 1990, Archivos espanoles de urologia,
W Cawello, and H Schweer, and B Dietrich, and H W Seyberth, and D Albrecht, and A Fox, and H Hohmuth
Intracavernous injection of prostaglandin E1 in spinal cord injured patients with erectile dysfunction. A preliminary report.
December 1995, Paraplegia,
W Cawello, and H Schweer, and B Dietrich, and H W Seyberth, and D Albrecht, and A Fox, and H Hohmuth
[Intracavernous auto-injection of prostaglandin E1 for diagnosis and treatment of erectile dysfunction].
April 1994, Harefuah,
W Cawello, and H Schweer, and B Dietrich, and H W Seyberth, and D Albrecht, and A Fox, and H Hohmuth
Intracavernous injection of prostaglandin E1 plus procaine in the treatment of erectile dysfunction.
October 1994, The Journal of urology,
W Cawello, and H Schweer, and B Dietrich, and H W Seyberth, and D Albrecht, and A Fox, and H Hohmuth
Intracavernous injection of prostaglandin E1 is effective in patients with erectile dysfunction not responding to phosphodiseterase 5 inhibitors.
December 2005, Acta medica Okayama,
Copied contents to your clipboard!